Result description
PRIME developed thermal biosensors with a potential for application in fundamental science and healthcare. Based on our patented technology, the sensing elements consist of a capture antibody crosslinked to the base floor of the #microfluidic channel, and a detection antibody bioconjugated to the surface of a NIR-absorbing #nanoparticle (NP). When the sample is loaded, the analyte, if present, interacts with the capture antibody and is retained in the channel. Nanoparticles are subsequently retained by the detection antibody in the presence of the analyte. In a later step, the channels are irradiated with an NIR laser. This incoming light is transduced into heat, and this heat generated can change a colorimetric thermal transducer which is the optical detection element. We have demonstrated the sensing concept for the detection of Carcinoembryonic Antigen (CEA), a common cancer marker, using a functional prototype.
A Thermo-ELISA coupled to a thermoresponsive cholesteric liquid crystal polymer layer that serves as a thermal transducer for optical detection of the analyte with selectivity and ultrasensitivity.
Addressing target audiences and expressing needs
- We are sharing our knowledge
We need to develop a certified developing system and achieve clinical validation of ths technology for specific clinically relevant analytes.
- Others/ No specific audience
R&D, Technology and Innovation aspects
The technology is still at a very early stage of development. It has been fine-tuned for the detection of a tumour marker, but a market study is needed to select different analytes for which an in-line measurement with the detection limits that our methodology can achieve.
Result submitted to Horizon Results Platform by AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS